Compare ARTL & AIXI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ARTL | AIXI |
|---|---|---|
| Founded | 2011 | 2001 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5M | 3.7M |
| IPO Year | N/A | 2022 |
| Metric | ARTL | AIXI |
|---|---|---|
| Price | $1.31 | $0.23 |
| Analyst Decision | Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $30.00 | N/A |
| AVG Volume (30 Days) | 28.9K | ★ 1.6M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $26.84 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.85 | $0.19 |
| 52 Week High | $28.60 | $4.94 |
| Indicator | ARTL | AIXI |
|---|---|---|
| Relative Strength Index (RSI) | 40.83 | 38.13 |
| Support Level | $0.90 | $0.19 |
| Resistance Level | $1.85 | $0.39 |
| Average True Range (ATR) | 0.14 | 0.04 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 34.78 | 11.33 |
Artelo Biosciences Inc is a United States-based development-stage biopharmaceutical company. It is engaged in the development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, a family of receptors & neurotransmitters that form a biochemical communication network in the body. It is focused on discovering, licensing, developing, & commercializing treatments that control endocannabinoid systems. The company pursues technologies & programs that offer proprietary approaches to cannabinoid-based therapies, & those derived from the cannabis plant & synthetic cannabinoids, as well as new chemical entities & compounds. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare & orphan disease.
XIAO-I Corp is an AI industrialization company focusing on the AI Cognitive Intelligence platform. The platform combines six core technologies including Natural Language Processing, Speech Processing, Computer Vision, Machine Learning, Affective Computing, Data Intelligence, and Hyper- automation. Based on the platform, The company developed products and solutions in the fields of Al+ Contact Center, Al+ Finance, Al+ City Public Service, Al+ Architecture, Al+ Metaverse, Al+ Manufacturing, and Al+ Healthcare. It generates revenue from the sale of software products and services, M&S services, and the sale of cloud platform products.